<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00437567</url>
  </required_header>
  <id_info>
    <org_study_id>SZMC/CH/32007</org_study_id>
    <nct_id>NCT00437567</nct_id>
  </id_info>
  <brief_title>Prebiotics in the Prevention of Necrotizing Enterocolitis</brief_title>
  <official_title>Prebiotics vs. Placebo in the Prevention of Necrotizing Enterocolitis in Premature Neonates</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shaare Zedek Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shaare Zedek Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Necrotizing enterocolitis (NEC) is the most common gastrointestinal catastrophe affecting
      10-15% of premature neonates of &lt;1500 gm. NEC is a disease of the immature intestine,
      characterized by impaired mucosal barrier function leading to increased gut permeability. We
      have previously demonstrated a protective effect of probiotic administration against the
      development of NEC. Others have shown that prebiotics can stimulate natural production of
      bifidobacteria and lactobacillus in the preterm gut. We have therefore hypothesized that
      prophylactic administration of prebiotics would also provide protection against necrotizing
      enterocolitis in the premature neonate, without the potential for sepsis which has been
      reported on rare occasions with probiotics administration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specifically, we hope to demonstrate that fewer of the babies who are treated with
      galacto-oligosaccharides (GOS) will develop NEC as compared with controls.

      Preterm neonates, &lt;1750 gm birth weight will potentially be candidates for study. They will
      be randomly assigned to receive one of two milk additives from the time enteral feeds are
      begun until 35 weeks post-conceptual age: prebiotics (GOS) or placebo (water). All infants
      will be followed prospectively for signs of feeding intolerance and/or development of NEC.
      These will be compared between the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Necrotizing Enterocolitis</measure>
    <time_frame>yearly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fecal calprotectin, urine IFABP</measure>
    <time_frame>end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NEC related morbidity, ie. perforation, surgery [including peritoneal drain placement]</measure>
    <time_frame>yearly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stool bifidobacteria</measure>
    <time_frame>End of study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Necrotizing Enterocolitis</condition>
  <arm_group>
    <arm_group_label>Prebiotics</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Babies randomized to this arm will receive galacto-oligosaccharide supplements</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Babies randomized to this arm will receive placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Galacto-oligosaccharide (GOS)</intervention_name>
    <description>Treatment group to receive 1.3 gm/kg/day GOS from initiation of enteral feeds until 35 weeks post-conceptual age.</description>
    <arm_group_label>Prebiotics</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Similar quantity of sterile water to be added to milk</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Preterm neonates

          -  &lt; 1750 gm birth weight

        Exclusion Criteria:

          -  Infants who are deemed unlikely to survive

          -  Infants with significant congenital malformations

          -  Infants with other gastrointestinal problems
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>7 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cathy Hammerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shaare Zedek Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cathy Hammerman, MD</last_name>
    <phone>9722 666-6238</phone>
    <email>cathy@cc.huji.ac.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alona Bin-nun, MD</last_name>
    <phone>97250 868-5757</phone>
    <email>alona.binnun@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cathy Hammerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alona Bin-nun, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Bin-Nun A, Bromiker R, Wilschanski M, Kaplan M, Rudensky B, Caplan M, Hammerman C. Oral probiotics prevent necrotizing enterocolitis in very low birth weight neonates. J Pediatr. 2005 Aug;147(2):192-6.</citation>
    <PMID>16126048</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2007</study_first_submitted>
  <study_first_submitted_qc>February 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2007</study_first_posted>
  <last_update_submitted>January 2, 2014</last_update_submitted>
  <last_update_submitted_qc>January 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shaare Zedek Medical Center</investigator_affiliation>
    <investigator_full_name>Cathy Hammerman</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>galacto-oligosaccharides</keyword>
  <keyword>prebiotics</keyword>
  <keyword>NEC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enterocolitis</mesh_term>
    <mesh_term>Enterocolitis, Necrotizing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

